Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia

Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0220121. doi: 10.1128/aac.02201-21. Epub 2022 Dec 19.

Authors

Affiliations

¹ Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
² Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.

No abstract available

Keywords: community-acquired bacterial pneumonia; omadacycline; pharmacokinetics.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bacteria
Community-Acquired Infections* / drug therapy
Community-Acquired Infections* / microbiology
Humans
Pneumonia, Bacterial* / drug therapy
Tetracyclines

Substances

omadacycline
Anti-Bacterial Agents
Tetracyclines